StockData
Corcept Therapeutics Inc logo

Corcept Therapeutics Inc (CORT) stock

CORTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 11/30537% above fair value
$70.07+0.85 (+1.23%)

Close on Nov 17, 2026Market cap $7.57BP/E 166.8Yield –

Corcept Therapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Corcept Therapeutics's pe ratio was 177.4× on Nov 11, 2026, against 91.3× a year earlier. Over the last 5 years it ranged from 20.3× to 327.1×, with a median of 36.5×.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 2026177.4×+137.4
2025Dec 31, 202540.0×+0.0
2024Dec 31, 202440.0×−0.1
2023Dec 29, 202340.1×+19.8
2022Dec 30, 202220.3×−3.5
2021Dec 31, 202123.9×−5.5
2020Dec 31, 202029.4×+12.6
2019Dec 31, 201916.8×+5.6
2018Dec 31, 201811.2×−51.0
2017Dec 29, 201762.3×−119.2
2016Dec 30, 2016181.5×–

More Corcept Therapeutics figures

See a number that looks wrong?